DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a serine-threonine kinase crucial for cancer cell processes.
• DNA-PKcs is identified as a potential therapeutic target for differentiated thyroid cancer (DTC).

Purpose of the Study:

• To evaluate the efficacy of the DNA-PKcs inhibitor M3814 in differentiated thyroid cancer (DTC) models.
• To assess M3814 as a single agent and in combination therapy for DTC.

Main Methods:

• In vitro cytotoxicity assays were performed on four DTC cell lines (TPC1, K1, FTC-133, FTC-238).
• Cell cycle analysis was conducted to determine M3814's effect on DTC cell proliferation.
• In vivo studies utilized a K1 tumor model for monotherapy and an FTC-133 xenograft model for combination therapy with lenvatinib.

Main Results:

• M3814 induced dose-dependent cytotoxicity in all tested DTC cell lines.
• M3814 treatment resulted in S-phase cell cycle arrest in DTC cells.
• M3814 monotherapy inhibited K1 tumor growth; combination with lenvatinib showed synergistic effects and superior efficacy in an FTC-133 xenograft model.

Conclusions:

• M3814 exhibits significant potential as a therapeutic agent for differentiated thyroid cancer.
• M3814 demonstrates efficacy both as a standalone treatment and in combination with other therapies like lenvatinib for DTC.